Compare Artra Group Corp. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROCE of 1.24%
- The company has been able to generate a Return on Capital Employed (avg) of 1.24% signifying low profitability per unit of total capital (equity and debt)
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -12.20
3
Poor long term growth as Operating profit has grown by an annual rate 19.68% of over the last 5 years
4
Negative results in Jun 26
5
With ROE of 10.35%, it has a fair valuation with a 1.21 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,037 Million (Micro Cap)
12.00
NA
0.00%
-0.30
10.35%
1.28
Revenue and Profits:
Net Sales:
649 Million
(Quarterly Results - Jun 2026)
Net Profit:
68 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.69%
0%
2.69%
6 Months
33.57%
0%
33.57%
1 Year
-5.45%
0%
-5.45%
2 Years
39.42%
0%
39.42%
3 Years
-10.33%
0%
-10.33%
4 Years
2.69%
0%
2.69%
5 Years
-38.78%
0%
-38.78%
Artra Group Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.88%
EBIT Growth (5y)
19.68%
EBIT to Interest (avg)
0.64
Debt to EBITDA (avg)
2.55
Net Debt to Equity (avg)
0.17
Sales to Capital Employed (avg)
1.55
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.45%
ROE (avg)
1.63%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.21
EV to EBIT
8.11
EV to EBITDA
5.39
EV to Capital Employed
1.30
EV to Sales
0.37
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
16.06%
ROE (Latest)
10.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
649.10
903.70
-28.17%
Operating Profit (PBDIT) excl Other Income
85.80
66.00
30.00%
Interest
2.50
3.50
-28.57%
Exceptional Items
0.80
0.00
Consolidate Net Profit
67.80
135.30
-49.89%
Operating Profit Margin (Excl OI)
98.70%
50.40%
4.83%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -28.17% vs -10.39% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -49.89% vs 571.43% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,927.20
4,234.40
-7.25%
Operating Profit (PBDIT) excl Other Income
246.20
160.00
53.88%
Interest
13.90
13.70
1.46%
Exceptional Items
0.50
-28.60
101.75%
Consolidate Net Profit
258.30
-36.70
803.81%
Operating Profit Margin (Excl OI)
35.90%
1.30%
3.46%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -7.25% vs -5.85% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 803.81% vs -167.96% in Dec 2024
About Artra Group Corp. 
Artra Group Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






